For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
LifeStance Health Group Inc (NASDAQ: LFST) closed the day trading at $4.27 up 1.67% from the previous closing price of $4.2. In other words, the price has increased by $1.67 from its previous closing price. On the day, 2.19 million shares were traded. LFST stock price reached its highest trading level at $4.2988 during the session, while it also had its lowest trading level at $4.1808.
Ratios:
For a better understanding of LFST, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.22. For the most recent quarter (mrq), Quick Ratio is recorded 1.47 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.29.
On April 08, 2025, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $9.
On April 03, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $8.Canaccord Genuity initiated its Buy rating on April 03, 2025, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Ramtekkar Ujjwal sold 9,519 shares for $5.17 per share. The transaction valued at 49,213 led to the insider holds 103,916 shares of the business.
Ramtekkar Ujjwal bought 9,519 shares of LFST for $49,213 on Jun 16 ’25. On Jun 05 ’25, another insider, Ramtekkar Ujjwal, who serves as the Chief Medical Officer of the company, sold 16,000 shares for $5.94 each. As a result, the insider received 95,040 and left with 113,435 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LFST now has a Market Capitalization of 1660500480 and an Enterprise Value of 2007394176. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.29 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 1.564 whereas that against EBITDA is 39.438.
Stock Price History:
The Beta on a monthly basis for LFST is 1.15, which has changed by -0.22924185 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, LFST has reached a high of $8.61, while it has fallen to a 52-week low of $4.12. The 50-Day Moving Average of the stock is -18.48%, while the 200-Day Moving Average is calculated to be -36.53%.
Shares Statistics:
Over the past 3-months, LFST traded about 2.07M shares per day on average, while over the past 10 days, LFST traded about 2778480 shares per day. A total of 388.83M shares are outstanding, with a floating share count of 116.89M. Insiders hold about 69.94% of the company’s shares, while institutions hold 36.32% stake in the company. Shares short for LFST as of 1751241600 were 8670558 with a Short Ratio of 4.18, compared to 1748563200 on 9164000. Therefore, it implies a Short% of Shares Outstanding of 8670558 and a Short% of Float of 10.0600004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of LifeStance Health Group Inc (LFST) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.16 and $0.16 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.19, with 1.0 analysts recommending between $0.19 and $0.19.
Revenue Estimates
7 analysts predict $345.05M in revenue for the current quarter. It ranges from a high estimate of $349.67M to a low estimate of $339.75M. As of the current estimate, LifeStance Health Group Inc’s year-ago sales were $312.33MFor the next quarter, 7 analysts are estimating revenue of $359.45M. There is a high estimate of $365.9M for the next quarter, whereas the lowest estimate is $355.22M.
A total of 8 analysts have provided revenue estimates for LFST’s current fiscal year. The highest revenue estimate was $1.42B, while the lowest revenue estimate was $1.4B, resulting in an average revenue estimate of $1.41B. In the same quarter a year ago, actual revenue was $1.25BBased on 8 analysts’ estimates, the company’s revenue will be $1.61B in the next fiscal year. The high estimate is $1.64B and the low estimate is $1.57B.
